UTP20: A Protein Involved in Cancer Growth and Metastasis (G27340)

Target Name: UTP20

NCBI ID: G27340

UTP20

UTP20: A Protein Involved in Cancer Growth and Metastasis

UTP20 is a protein that is expressed in various tissues throughout the body, including the brain, heart, and gastrointestinal tract. It is a key regulator of the cell cycle, and its levels have been implicated in many diseases, including cancer. In addition, UTP20 has also been shown to play a role in metastasis, which is the process by which cancer cells spread throughout the body.

Recent studies have suggested that UTP20 may be a drug target or biomarker for several different types of cancer, including breast, lung, and ovarian cancer. This is because UTP20 has been shown to be involved in a variety of cellular processes that are important for cancer growth and progression.

One of the key mechanisms by which UTP20 is involved in cancer growth is its role as a regulator of the cell cycle. The cell cycle is the process by which a cell grows and replicates, and it is a critical factor in the development and progression of cancer. UTP20 has been shown to play a key role in regulating the length and structure of the cell cycle, which can have a significant impact on the growth and development of cancer cells.

In addition to its role in regulating the cell cycle, UTP20 has also been shown to be involved in the process of cell adhesion. This is the process by which cells stick together and form tissues, and it is a critical factor in the development and maintenance of tissues and organs. UTP20 has been shown to play a key role in regulating cell adhesion, which can again have a significant impact on the growth and development of cancer cells.

Another mechanism by which UTP20 is involved in cancer growth is its role as a regulator of the apoptosis pathway. The apoptosis pathway is the process by which cells die and are removed from the body, and it is a critical factor in the regulation of cell growth and differentiation. UTP20 has been shown to play a key role in regulating apoptosis, which can again have a significant impact on the growth and development of cancer cells.

In addition to its role in regulating the cell cycle, UTP20 has also been shown to be involved in the process of angiogenesis. This is the process by which new blood vessels form in the body, and it is a critical factor in the development and maintenance of tissues and organs. UTP20 has been shown to play a key role in regulating angiogenesis, which can again have a significant impact on the growth and development of cancer cells.

Finally, UTP20 has also been shown to be involved in the process of metastasis. Metastasis is the process by which cancer cells spread throughout the body and can lead to the development of new diseases. UTP20 has been shown to play a key role in the regulation of metastasis, which can again have a significant impact on the growth and development of cancer cells.

In conclusion, UTP20 is a protein that is involved in a variety of cellular processes that are important for cancer growth and progression. As a result, UTP20 may be a drug target or biomarker for several different types of cancer. Further research is needed to fully understand the role of UTP20 in cancer and to develop effective treatments.

Protein Name: UTP20 Small Subunit Processome Component

Functions: Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome. Involved in 18S pre-rRNA processing. Associates with U3 snoRNA

The "UTP20 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about UTP20 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets